Peptide HRH
Peptide HRH is a polypeptide that specifically binds to VEGF receptors. Peptide HRH inhibits VEGF-stimulated endothelial cell proliferation. Peptide HRH inhibits angiogenesis and suppresses corneal neovascularization. Peptide HRH can be used in anti-angiogenesis related studies.
For research use only. We do not sell to patients.
- CAS No.: 1228536-06-8
- Formula: C64H104N28O16
- Molecular Weight:1521.69
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All VEGFR Isoforms
More
Biological Activity
Peptide HRH (0.95-3.85 μg/μL; 96 h) dose-dependently inhibits the proliferation of VEGF-stimulated human umbilical vein endothelial cells (HUVECs)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human umbilical vein endothelial cells (HUVECs) stimulated with VEGF
-
Concentration:0.95; 1.9; 3.85 μg/μL
-
Incubation Time:96 h
-
Result:Suppressed the proliferation of VEGF-stimulated HUVECs in a dose-dependent manner.
Peptide HRH (10 μg/μL; topical eye drops; four times per day; 14 days) significantly inhibits corneal neovascularization in the alkali-burned rat corneal model[1].
Peptide HRH (10 μg/μL; topical eye drops; four times per day; 14 days) significantly inhibits corneal neovascularization in the suture-induced rat corneal model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, alkali-burned corneal model)[1]
-
Dosage:10 μg/μL
-
Administration:topical eye drops; four times per day; 14 days
-
Result:Significantly reduced corneal neovascularization area from days 3 to 14 post-burn.
Kept most of the corneal stroma free of blood vessels.
-
Animal Model:Sprague-Dawley (male, suture-induced corneal model)[1]
-
Dosage:10 μg/μL
-
Administration:topical eye drops; four times per day; 14 days
-
Result:Significantly reduced maximum vessel length and total corneal neovascularization area from days 3 to 14 post-suture.
Chemical Information
-
CAS No. 1228536-06-8
-
Molecular Weight 1521.69
-
Formula C64H104N28O16
-
Sequence
His-Arg-His-Thr-Lys-Gln-Arg-His-Thr-Ala-Leu-His
-
Sequence Shortening
HRHTKQRHTALH
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Peptide HRH Related Classifications
HY-P11775 Related Classifications
Powered by Bioz